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Summary
Severe sepsis is often accompanied by a transient immune paralysis, which
is associated with enhanced susceptibility to secondary infections and
poor clinical outcomes. The functional impairment of antigen-presenting
cells is considered to be a major hallmark of this septic immunosuppres-
sion, with reduced HLA-DR expression on circulating monocytes serving
as predictor of mortality. Unconventional lymphocytes like cd T-cells have
the potential to restore immune defects in a variety of pathologies includ-
ing cancer, but their use to rescue sepsis-induced immunosuppression has
not been investigated. Our own previous work showed that Vc9/Vd2+ cd
T-cells are potent activators of monocytes from healthy volunteers
in vitro, and in individuals with osteoporosis after first-time administra-
tion of the anti-bone resorption drug zoledronate in vivo. We show here
that zoledronate readily induces upregulation of HLA-DR, CD40 and
CD64 on monocytes from both healthy controls and sepsis patients,
which could be abrogated by neutralising the pro-inflammatory cytokines
interferon (IFN)-c and tumour necrosis factor (TNF)-a in the cultures. In
healthy controls, the upregulation of HLA-DR on monocytes was propor-
tional to the baseline percentage of Vc9/Vd2 T-cells in the peripheral
blood mononuclear cell population. Of note, a proportion of sepsis
patients studied here did not show a demonstrable response to zole-
dronate, predominantly patients with microbiologically confirmed blood-
stream infections, compared with sepsis patients with more localised
infections marked by negative blood cultures. Taken together, our results
suggest that zoledronate can, at least in some individuals, rescue immuno-
suppressed monocytes during acute sepsis and thus may help improve
clinical outcomes during severe infection.
Keywords: gammadelta T-cells; immunosuppression; monocytes; sepsis;
zoledronate.
Introduction
The immune system has evolved to sense and fight a
myriad of viral, bacterial, fungal and parasitic pathogens.
Early inflammatory responses to infection aim to control
and clear the causative organism, yet there is emerging
evidence in critically ill patients of a subsequent, or paral-
lel, transition to a blunted hypoimmune state.1 This
acquired immune paresis is believed to render individuals
with severe sepsis susceptible to secondary, often hospital-
acquired, infections during recovery from the initial
insult.2 While previous interventions aimed at targeting
the immediate hyperinflammatory phase (‘cytokine
storm’) to improve outcomes from sepsis, often with
little success, more recent studies focus on utilising
immunotherapeutic approaches directed towards this
somewhat paradoxical immunosuppression.2–4 Addressing
immunosuppression brings significant survival benefits in
cancer,5 yet it remains to be shown to be effective in
reducing non-cancer morbidity. The lack of advance in
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treating infectious diseases is likely due to the challenges
in identifying and effectively targeting those patients that
would benefit most from intervention, as well as a pau-
city of safe therapeutic options.
Reduced HLA-DR expression by monocytes has
become a hallmark of sepsis immunosuppression, and is
being used not only as clinical predictor of poor out-
comes but also as potential target for novel interven-
tions.6–9 A series of clinical trials have aimed at restoring
myeloid cell functions, including HLA-DR levels on
monocytes, in sepsis patients by using recombinant
cytokines such as interferon (IFN)-c and granulocyte
macrophage colony-stimulating factor (GM-CSF), with
mixed results.10–12 However, despite more than two dec-
ades of basic and clinical research in this area, no cyto-
kine therapy has yet been shown to reduce mortality in
sepsis patients. Administration of cytokines with pleiotro-
pic roles in the immune system is prone to give rise to
unwanted side-effects. Targeted delivery of immunothera-
peutic drugs is therefore desirable to minimise off-target
effects. In this respect, those cellular mechanisms are of
particular interest that allow direct and contact-dependent
delivery of effector molecules in vivo. One such approach
is the delivery of immunomodulatory effector molecules
by unconventional T-cells such as cd T-cells.
Vc9/Vd2 T-cells typically comprise 1%–5% of circulat-
ing T-cells in human blood, and are potent producers of
pro-inflammatory cytokines including IFN-c, tumour
necrosis factor (TNF)-a and GM-CSF with activity on
myeloid cells.13–16 A major physiological role of Vc9/Vd2
T-cells is the sensing of microbial pathogens that produce
the isoprenoid precursor (E)-4-hydroxy-3-methyl-but-2-
enyl pyrophosphate (HMB-PP), which include most
Gram-negative and many Gram-positive bacteria.17 How-
ever, Vc9/Vd2 T-cells also readily respond to stimulation
with zoledronate, a clinically approved drug used success-
fully in patients with malignant and non-malignant bone
resorption disorders.17,18 This Vc9/Vd2 T-cell response is
dependent on monocyte uptake of zoledronate19 and
involves the interruption of the intracellular mevalonate
pathway, leading to accumulation of upstream intermedi-
ates such as isopentenyl pyrophosphate and recognition
of sensitised monocytes via the butyrophilin-like molecule
BTN3 by the Vc9/Vd2 T-cell receptor.17,20,21
In co-culture experiments, cd T-cells activate mono-
cytes, promote their survival, induce upregulation of
markers associated with antigen-presenting cells (APCs)
including HLA-DR, and enhance their APC function.13
Clinical evidence in support of such a mechanism comes
from our own study in osteoporosis patients demonstrat-
ing that administration of zoledronate in otherwise
healthy individuals increases expression of APC markers
on circulating monocytes in vivo and boosts plasma levels
of IFN-c, TNF-a and GM-CSF.22 We here tested the
potential of zoledronate to activate peripheral monocytes
in patients with acute sepsis and provide evidence that
zoledronate treatment helps upregulate the expression of
HLA-DR and other APC markers on monocytes in vitro.
Our findings open potentially new therapeutic avenues
toward rescuing the immunosuppressed state of acutely ill
patients.
Materials and methods
Ethics statement
Recruitment of sepsis patients was approved by the
Health and Care Research Wales Research Ethics Com-
mittee under reference 17/WA/0253, protocol number
SPON1609-17 and IRAS project ID 231993, and con-
ducted according to the principles expressed in the Decla-
ration of Helsinki. All participants provided written
informed consent for the collection of samples and their
subsequent analysis. A waiver of consent system was used
when patients were unable to provide prospective
informed consent due to the nature of their critical illness
or therapeutic sedation at the time of recruitment. In all
cases, retrospective informed consent was sought as soon
as the patient recovered and regained capacity. In cases
where a patient passed away before regaining capacity,
the initial consultee’s approval would stand. Recruitment
of healthy adult volunteers was approved by Cardiff
University’s School of Medicine Research Ethics Commit-
tee under reference 18/04.
Subjects
Sepsis patients were over 18 years old with a diagnosis of
sepsis according to the Third International Consensus
Definitions for Sepsis and Septic Shock (‘Sepsis-3’), were
cared for in the intensive care unit at the University
Hospital of Wales in Cardiff, and were recruited within
36 hr of the presumed onset of the infective illness when
they already had or would require arterial cannulation as
part of standard treatment. This study cohort comprised
a total of n = 24 sepsis patients, with an age ranging from
28 to 82 years (median 57 years), 708% of which were
female. Age- and gender-matched healthy donors served
as non-infected controls (n = 19; age range 25–66 years,
median 59 years; 579% female).
Patients were excluded if they were pregnant or breast-
feeding, or were females of childbearing age in whom a
pregnancy test had not been performed; if they had severe
immune deficiency, for example a diagnosis of AIDS or
treatment with anti-rejection transplant drugs or high-
dose corticosteroids; if they had haematological malig-
nancy or ongoing chemotherapy; if they had severe liver
failure (Child’s score III or worse); if they were adjudged
by the admitting clinician to be unlikely to survive for
the duration of the study period regardless of treatment;
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if they were admitted post-cardiac arrest; or if they had
an underlying impairment of higher function that would
make it impossible for informed consent to be given
upon recovery (e.g. severe learning disability).
Cell culture
The culture medium was RPMI-1640 supplemented with
2 mM L-glutamine, 1% sodium pyruvate, 50 lg/ml peni-
cillin/streptomycin and 10% foetal calf serum (Invitrogen,
Paisley, UK). Peripheral blood mononuclear cells (PBMCs)
were isolated from peripheral blood of healthy volunteers
using Lymphoprep (Axis-Shield, Dundee, UK) and cul-
tured with and without 10 µM zoledronate (Zometa;
Novartis, Basel, Switzerland) for 16 hr; a combination of
10 ng/ml recombinant IFN-c and 20 ng/ml recombinant
TNF-a (both Miltenyi, Woking, UK) was used as positive
control. For blocking experiments, anti-IFN-c (B27; Biole-
gend, London, UK) and sTNFR p75-IgG1 fusion protein
(etanercept/Enbrel; Amgen, Cambridge, UK) were used at
10 lg/ml each. Cell culture supernatants were analysed in
duplicate on a CLARIOstar microplate reader (BMG Lab-
tech, Aylesbury, UK), using a sandwich ELISA kit for the
detection of TNF-a (Invitrogen).
Flow cytometry
Cells were acquired on a BD LSRFortessa flow cytometer
(BD Biosciences, Wokingham, UK) and analysed with
FLOWJO version 10 (TreeStar, Ashland, OR, USA). Single
cells of interest were gated based on their appearance in
side and forward scatter area/height, exclusion of live/
dead staining (fixable Aqua; Invitrogen) and surface stain-
ing (CD3 CD19 CD14+ monocytes, Vd2+ CD3+ cd
T-cells). The following mAbs were used for surface
labelling: anti-CD3 (SP34-2), anti-CD64 (101) and anti-
TCR-Vd2 (B6) from BD Biosciences; anti-TCR-pan-cd
(Immu510) and anti-CD40 (mAB89) from Beckman
Coulter, High Wycombe, UK; and anti-CD14 (M5E2),
anti-CD86 (IT22) and anti-HLA-DR (L243) from
Biolegend.
Statistics
Statistical analyses were performed using GRAPHPAD Prism
6.0. Variables were tested for normal distribution using
D’AgostinoPearson tests. All statistical tests were two-
tailed; differences were considered significant at P < 005.
Results
Zoledronate treatment of PBMCs induces activation
of monocytes
Our earlier research demonstrated that purified human
cd T-cells readily induce activation of co-cultured mono-
cytes, when stimulated with the microbial metabolite
HMB-PP.13 We here tested whether this effect on mono-
cytes could be reproduced in PBMC cultures and by
replacing HMB-PP with the clinically approved drug zole-
dronate. Indeed, overnight stimulation of PBMCs with
zoledronate led to a general activation of the monocyte
population as evidenced by upregulation of HLA-DR,
CD40 and CD64; upregulation of CD86 failed to reach
statistical significance (Fig. 1).
The zoledronate-dependent effect on monocytes was
largely abrogated in the presence of neutralising reagents
against IFN-c and TNF-a, indicating that these two
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Figure 1. Zoledronate-induced activation of healthy monocytes. Peripheral blood mononuclear cells (PBMCs) from healthy volunteers were cul-
tured in medium alone or treated overnight with zoledronate in the absence (n = 19) or presence of anti-interferon (IFN)-c and sTNFR (Inhibi-
tors; n = 15), or with a combination of recombinant IFN-c and tumour necrosis factor (TNF)-a (Cytokines; n = 11). Monocyte activation was
calculated as fold upregulation of the indicated surface markers (determined as mean fluorescence intensities), in relation to medium controls
with a value of 1, and is shown as box and whisker plots (min to max). Data were analysed using KruskalWallis tests, together with Dunn’s
multiple comparison post hoc tests; asterisks indicate significant differences: *P < 005; **P < 001; ***P < 0001.
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cytokines were major drivers of monocyte activation in
PBMC cultures treated with zoledronate. As control,
incubation of PBMCs with recombinant IFN-c and TNF-
a led to a similarly pronounced upregulation of HLA-
DR, CD40, CD64 and CD86 on monocytes as seen in
zoledronate-treated cultures (Fig. 1). In further support
of the key role for cd T-cells in mediating the observed
effects on monocytes, the extent of HLA-DR upregulation
achieved in zoledronate-treated PBMC cultures correlated
directly with the original proportion of Vd2+ T-cells in
the blood from healthy individuals (Fig. 2). Upregulation
of CD40, CD64 and CD86 followed a similar trend but
was much less pronounced.
Zoledronate induces activation of monocytes from
sepsis patients
Loss of HLA-DR surface expression is a well-known phe-
nomenon in sepsis, as surrogate marker of immunosup-
pression and predictor of poor outcomes.6–9 Here,
monocytes in sepsis patients expressed lower levels of
HLA-DR and CD86 during the first 36 hr of presenting
with acute illness, compared with healthy controls
(Fig. 3), suggesting functional defects in those patients. In
PBMC cultures, zoledronate treatment led to an upregula-
tion of HLA-DR as well as CD40 and CD64 on sepsis
monocytes, which at least in the case of HLA-DR and
CD40 could be inhibited by the addition of neutralising
reagents against IFN-c and TNF-a (Fig. 4). In accordance
with the role of TNF-a in these stimulation experiments,
treatment of PBMCs from sepsis patients with zole-
dronate led an increased release of TNF-a into the culture
supernatant (Fig. 5).
Patients with positive blood cultures have lower
responses to zoledronate
Overall, there was substantial patient-to-patient variation
with regard to the expression of surface markers on circu-
lating monocytes and their potential to respond to zole-
dronate stimulation. While in some individuals
zoledronate induced substantial upregulation of APC
markers (‘high responders’), in others zoledronate
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Figure 2. The frequency of blood cd T-cells determines the degree
of monocyte activation in response to zoledronate. Peripheral blood
mononuclear cells (PBMCs) from healthy volunteers (n = 19) were
cultured in medium alone or treated overnight with zoledronate.
Monocyte activation was calculated as fold upregulation of the indi-
cated surface markers (determined as mean fluorescence intensities),
in relation to medium controls with a value of 1, and is shown in
relation to the frequency of cd T-cells in the donors’ blood. Data
were analysed using linear regression.
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Figure 3. Peripheral monocytes in sepsis patients express reduced levels of HLA-DR, CD40, CD64 and CD86. Blood from adult sepsis patients
(n = 30) and from age- and gender-matched healthy volunteers (n = 19) was analysed by flow cytometry for expression of the indicated surface
markers on peripheral CD14+ monocytes. Data are shown as mean fluorescence intensities (MFIs) and were analysed using MannWhitney tests;
asterisks indicate significant differences: *P < 005; **P < 001; ***P < 0001.
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treatment had only very little effect (‘low responders’;
Fig. 6). This variable responsiveness did not correlate with
the severity of the clinical symptoms as assessed by
APACHE II scores (data not shown). In addition, it was
independent of the actual cd T-cell stimulus provided
in vitro as exposure to zoledronate and HMB-PP induced
similar responses (Fig. 7). However, monocytes from sep-
sis patients with systemic bacterial infections as confirmed
by positive blood cultures showed only very little respon-
siveness to zoledronate, compared with sepsis patients
with more localised infections marked by negative blood
cultures (Fig. 8). Of note, there were no quantitative
differences in peripheral Vc9/Vd2 T-cell or monocyte
levels between patients with negative and positive blood
cultures that could have explained this phenomenon (data
not shown).
Discussion
The present study is the first demonstration that experi-
mental exposure of human PBMCs to the anti-bone
resorption drug zoledronate drives upregulation of APC
markers on monocytes from both healthy individuals and
patients with acute sepsis. These findings extend our ear-
lier investigations in cd T-cell–monocyte co-cultures
in vitro13 and in zoledronate-treated individuals with
osteoporosis in vivo.22 Taken together, we conclude that
zoledronate treatment has the potential, at least partially,
to rescue aspects of the pronounced immunosuppression
frequently observed in sepsis patients and may thereby
help improve clinical outcomes.
Our data are consistent with the view that once taken
up by monocytes, zoledronate causes intracellular accu-
mulation of metabolites of the mevalonate pathway such
as isopentenyl pyrophosphate, which is then sensed by
Vc9/Vd2 T-cells. Vc9/Vd2 T-cells produce copious
amounts of pro-inflammatory cytokines like IFN-c and
TNF-a upon activation, which in turn affect the function
of bystander cells in the microenvironment, including
monocytes, neutrophils and local tissue cells.16,23,24 This
model is supported by the present observation that neu-
tralising the effects of IFN-c and TNF-a in zoledronate-
treated PBMC cultures blocked the upregulation of HLA-
DR and CD40 on monocytes from both healthy individ-
uals and patients with severe sepsis, and that exposure of
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Figure 4. Zoledronate-induced activation of monocytes from sepsis patients. Peripheral blood mononuclear cells (PBMCs) from patients with
acute sepsis were cultured in medium alone or treated overnight with zoledronate in the absence (n = 24) or presence of anti-interferon (IFN)-c
and sTNFR (Inhibitors; n = 24), or with a combination of recombinant IFN-c and tumour necrosis factor (TNF)-a (Cytokines; n = 17). Mono-
cyte activation was calculated as fold upregulation of the indicated surface markers (determined as mean fluorescence intensities), in relation to
medium controls with a value of 1, and is shown as box plots (min to max). Data were analysed using a KruskalWallis test, together with
Dunn’s multiple comparison post hoc test; asterisks indicate significant differences: *P < 005; **P < 001; ***P < 0001.
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Figure 5. Zoledronate induces release of tumour necrosis factor
(TNF)-a by peripheral blood mononuclear cells (PBMCs). PBMCs
from patients with acute sepsis (n = 11) were cultured in medium
alone (– Zol) or treated overnight with zoledronate (+ Zol). Levels
of TNF-a released into the culture supernatants were determined by
ELISA. Data were analysed using a Wilcoxon matched pairs signed
rank test; ***P < 0001.
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sepsis PBMC to zoledronate led to an increased release
of TNF-a into the culture medium. While we were
unable to confirm the cellular source of TNF-a, our pre-
vious work suggests that TNF-a is produced by both
Vc9/Vd2 T-cells and monocytes under such condi-
tions.13,14 Unfortunately, the limited amounts of patient
blood available for the present study and the low num-
bers of Vc9/Vd2 T-cells in most samples (with a median
frequency of 058% among live PBMCs; data not shown)
did not allow us to assess directly markers of successful
Vc9/Vd2 T-cell activation. These limitations notwith-
standing, our findings support considerations to use
aminobisphosphonates like zoledronate – or related cd
T-cell-stimulating treatments such as HMB-PP analogues
or anti-BTN3 agonistic antibodies – as novel
immunotherapies in sepsis patients. However, care
should be taken to balance such potential benefits with
the risk of possible side-effects. While the pro-inflamma-
tory nature of cd T-cell responses will be able to boost
APCs and thus help rescue the underlying immunosup-
pression, the very nature of such responses may simulta-
neously give rise to an acute phase-like reaction, which
will have to be carefully mitigated.22,25,26 Also, while
zoledronate treatment clearly has stimulatory effects on
monocytes, others have shown that zoledronate-treated
monocytes and macrophages may become targets for cd
T-cell-mediated killing,27,28 thereby potentially limiting
the therapeutic window.
Strikingly, a proportion of sepsis patients studied here
did in fact not show a demonstrable response to zole-
dronate, predominantly patients with microbiologically
confirmed bloodstream infections. There was generally
good correlation between responses to zoledronate and
the microbial metabolite HMB-PP serving as control,
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Figure 6. Patient to patient variation in the responsiveness of monocytes to zoledronate stimulation. Peripheral blood mononuclear cells (PBMCs)
from patients with acute sepsis were cultured in medium alone (shaded histograms) or treated overnight with zoledronate in the absence (solid line)
or presence of anti-interferon (IFN)-c and sTNFR (dotted line; Inhibitors), or with a combination of recombinant IFN-c and tumour necrosis factor
(TNF)-a (red histograms; Cytokines). Data shown are representative of a ‘high responder’ (left panels) and a ‘low responder’ (right panel).
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thereby ruling out a potential defect in low responders
affecting zoledronate uptake by monocytes and/or its
intracellular mode of action. Low responsiveness to zole-
dronate in certain individuals has been described before,
most notably in patients with chronic lymphocytic
leukaemia or multiple myeloma.29,30 The underlying
mechanism for the unresponsiveness in blood culture-
positive sepsis patients remains unclear but may involve
a systemic dysfunction of cd T-cells and/or monocytes
as a result of the severe infection, differences in the
activity of the mevalonate pathway in monocytes, ele-
vated levels of regulatory T-cells or immunosuppressive
molecules, and genetic and environmental factors. More
research is needed to be able to stratify patients with
regard to the underlying pathology, nature of the infec-
tive organism (e.g. with regard to their potential to pro-
duce HMB-PP), treatment options and general
demographics, and identify those sepsis patients who
may benefit most from a zoledronate-based therapy.
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